<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443755</url>
  </required_header>
  <id_info>
    <org_study_id>05-004002</org_study_id>
    <secondary_id>R01DK041973</secondary_id>
    <secondary_id>KL2RR024151</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT00443755</nct_id>
  </id_info>
  <brief_title>Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance</brief_title>
  <official_title>Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether targeted pharmacological improvement of
      insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory
      cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with diabetes mellitus (DM) are disproportionately affected by atherothrombotic
      disorders, including cardiovascular, cerebrovascular, and peripheral vascular diseases.
      Atherothrombotic disease risk and mortality are also increased with metabolic syndrome, a
      constellation of risk factors present in more than 34% of adults, even in absence of
      diabetes. Yet, large clinical trials of diabetes therapies have shown that conventional
      cardiovascular disease (CVD) risk factors, specifically hyperglycemia and hypertension, do
      not fully account for increased CVD risk associated with DM.

      There may be an etiologic link among insulin resistance, inflammation and thrombotic events.
      This study seeks to determine if certain two diabetes medications (the insulin sensitizing
      medications) will affect certain biomarkers (or laboratory tests) for CVD in individuals with
      untreated DM or impaired fasting glucose.

      Patients will be screened for inclusion into this this double-blinded, randomized),
      placebo-controlled study. If inclusion criteria are met and exclusion criteria not met,
      patients will be enrolled in the the study. Half of the subjects will be randomized (like the
      flip of a coin) to take two insulin sensitizing, anti-diabetic drugs pioglitazone (Actos) and
      metformin (Glucophage) taken together for three months and the other half of the subjects
      will take corresponding placebo (dummy) tablets.

      Laboratory measurements will be obtained on the morning(s) following the two in-patient
      overnight stays in the Mayo Clinic Clinical Research Unit. The first stay will be at baseline
      and the second stay will be 3 months after baseline. Insulin sensitivity will be measured in
      the morning following a standardized meal the preceding night, and after an overnight fast.

      The changes (from baseline to 3 months) in insulin sensitivity, glycemic control, the lipid
      profile, thrombotic markers and inflammatory markers will be determined and compared between
      the two arms of the study (placebo versus insulin sensitizing drugs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit &amp; was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose Level</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Levels</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipid Profile</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Thrombotic Biomarker Fibrinogen</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Thrombotic Biomarker Plasminogen Activator Inhibitor-1 (PAI-1)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Inflammatory Biomarker Interleukin 6 (IL-6)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Inflammatory Biomarker C-Reactive Protein (CRP)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inflammatory Biomarker Tumor Necrosis Factor-alpha (TNF-α)</measure>
    <time_frame>Baseline, 3 month</time_frame>
    <description>TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Inflammatory Biomarker Adiponectin</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Body Mass Index</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Body Fat</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Body fat is reported as a percentage of body weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Fat-Free Mass (FFM)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Insulin Sensitizer Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets were used to match the active comparator drugs and dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.</description>
    <arm_group_label>Insulin Sensitizer Therapy</arm_group_label>
    <other_name>Fortamet</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage Extended Release (XR)</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Riomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.</description>
    <arm_group_label>Insulin Sensitizer Therapy</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  We will study 30 patients with Type 2 Diabetes or impaired fasting glucose (15 men &amp;
             15 women) who are &gt; 20 years old.

          -  Only patients who use lifestyle modification to manage their diabetes and are not on
             any oral hypoglycemic agents or insulin will be included.

          -  We will enroll subjects who have fasting glucose concentration greater than 100 mg/dl
             on two consecutive occasions and have a Body Mass Index between 27-36 kg/m^2.

        Exclusion Criteria:

          -  We will exclude patients whose blood glucose is above 180 mg/dl. This will avoid the
             need to perform home glucose monitoring and the potential of unblinding the study by
             the volunteers.

          -  Patients taking oral hypoglycemic agents or insulin would be excluded.

          -  Any diseases such as active cardiovascular disease, liver diseases, kidney failure
             (males with serum creatinine &gt;= 1.5mg/dl, females &gt;=1.4 mg/dl), active
             endocrinopathies, debilitating chronic disease, anemia, symptoms of undiagnosed
             illness, history of alcoholism (alcohol use &gt; 4oz/day) or substance abuse, chronic
             neurological diseases including Alzheimer's disease, stroke, etc, myopathies or any
             other active disease that may potentially affect the outcome measures.

          -  Patients on medicines such as beta blockers, corticosteroids, tricyclics,
             benzodiazepines, opiates, barbiturates, anticoagulants and any other drugs or
             preparations that may affect mitochondrial function will be excluded.

          -  People allergic to any of the class of drug such as lidocaine will also be excluded.

          -  People with pacemakers, certain aneurysm clips and claustrophobia will also be
             excluded as they cannot undergo magnetic resonance imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. Sreekumaran Nair, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>McCoy RG, Irving BA, Soop M, Srinivasan M, Tatpati L, Chow L, Weymiller AJ, Carter RE, Nair KS. Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. Mayo Clin Proc. 2012 Jun;87(6):561-70. doi: 10.1016/j.mayocp.2012.02.014. Erratum in: Mayo Clin Proc. 2013 Aug;88(8):903-4.</citation>
    <PMID>22677076</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <results_first_submitted>April 22, 2013</results_first_submitted>
  <results_first_submitted_qc>April 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2013</results_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>K. Sreekumaran Nair</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Inflammatory cytokine</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Thrombotic factors</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted between 8/19/2005 and 8/24/2010 at the Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <pre_assignment_details>48 Northern European Americans were assessed for eligibility and of those, 20 did not meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Sensitizer Therapy</title>
          <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline characteristics are reported for the subjects who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Insulin Sensitizer Therapy</title>
          <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="15.6"/>
                    <measurement group_id="B2" value="52.2" spread="18.2"/>
                    <measurement group_id="B3" value="52.4" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared.</description>
          <units>kilograms/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.43" spread="5.65"/>
                    <measurement group_id="B2" value="29.67" spread="3.34"/>
                    <measurement group_id="B3" value="31.00" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat-Free Mass</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.81" spread="14.29"/>
                    <measurement group_id="B2" value="46.67" spread="13.54"/>
                    <measurement group_id="B3" value="47.70" spread="13.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Fat</title>
          <units>Percentage of body weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.49" spread="5.92"/>
                    <measurement group_id="B2" value="43.26" spread="9.17"/>
                    <measurement group_id="B3" value="44.81" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Blood Glucose</title>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.25" spread="21.87"/>
                    <measurement group_id="B2" value="129.00" spread="26.32"/>
                    <measurement group_id="B3" value="127.68" spread="23.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <description>The HbA1c level reflects the average glucose (blood sugar) concentration over the previous 3 month period.</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.97" spread="0.71"/>
                    <measurement group_id="B2" value="6.25" spread="0.65"/>
                    <measurement group_id="B3" value="6.11" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose Infusion Rate (GIR)</title>
          <description>FFM is Fat Free Mass</description>
          <units>micromols/kilogram of FFM/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.28" spread="14.67"/>
                    <measurement group_id="B2" value="23.40" spread="15.27"/>
                    <measurement group_id="B3" value="22.86" spread="14.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin level</title>
          <units>micro International Units per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.68" spread="9.75"/>
                    <measurement group_id="B2" value="10.18" spread="5.70"/>
                    <measurement group_id="B3" value="12.82" spread="8.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipid Profile</title>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131.42" spread="54.76"/>
                    <measurement group_id="B2" value="135.00" spread="51.36"/>
                    <measurement group_id="B3" value="133.28" spread="51.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein-Cholesterol (HDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.33" spread="12.78"/>
                    <measurement group_id="B2" value="39.23" spread="8.74"/>
                    <measurement group_id="B3" value="41.20" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135.58" spread="26.17"/>
                    <measurement group_id="B2" value="132.46" spread="21.65"/>
                    <measurement group_id="B3" value="133.96" spread="23.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibrinogen</title>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="393.67" spread="78.63"/>
                    <measurement group_id="B2" value="418.92" spread="100.23"/>
                    <measurement group_id="B3" value="406.80" spread="89.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasminogen Activator Inhibitor 1 (PAI-1)</title>
          <units>nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.83" spread="22.01"/>
                    <measurement group_id="B2" value="55.85" spread="33.70"/>
                    <measurement group_id="B3" value="68.3" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.42" spread="0.43"/>
                    <measurement group_id="B2" value="0.43" spread="0.49"/>
                    <measurement group_id="B3" value="0.42" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interleukin-6 (IL-6)</title>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.46" spread="1.68"/>
                    <measurement group_id="B2" value="3.28" spread="4.79"/>
                    <measurement group_id="B3" value="2.88" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Necrosis Factor-alpha (TNF-α)</title>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.39" spread="0.57"/>
                    <measurement group_id="B2" value="2.98" spread="5.39"/>
                    <measurement group_id="B3" value="2.22" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adiponectin</title>
          <units>milligrams per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.08" spread="2.17"/>
                    <measurement group_id="B2" value="5.22" spread="2.13"/>
                    <measurement group_id="B3" value="5.63" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR)</title>
        <description>Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit &amp; was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR)</title>
          <description>Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit &amp; was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion.</description>
          <population>Per-protocol analysis</population>
          <units>micromols/kg of FFM/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.95" spread="8.60"/>
                    <measurement group_id="O2" value="1.68" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose Level</title>
        <description>Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose Level</title>
          <description>Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL).</description>
          <population>Per-protocol analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.96" spread="14.02"/>
                    <measurement group_id="O2" value="8.39" spread="22.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c)</title>
        <description>HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c)</title>
          <description>HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage.</description>
          <population>Per-protocol analysis</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.40"/>
                    <measurement group_id="O2" value="0.19" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Levels</title>
        <description>Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Levels</title>
          <description>Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL).</description>
          <population>Per-protocol analysis</population>
          <units>microIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.13" spread="7.47"/>
                    <measurement group_id="O2" value="1.38" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipid Profile</title>
        <description>Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipid Profile</title>
          <description>Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.58" spread="32.67"/>
                    <measurement group_id="O2" value="17.77" spread="28.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C-Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="6.75"/>
                    <measurement group_id="O2" value="-0.31" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.50" spread="15.29"/>
                    <measurement group_id="O2" value="4.62" spread="17.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value is for comparison between groups of the mean change in triglyceride levels.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value is for comparison between groups of the mean change in HDL-C levels.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value is for comparison between groups of mean change in non-HDL-C levels.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Thrombotic Biomarker Fibrinogen</title>
        <description>Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Thrombotic Biomarker Fibrinogen</title>
          <description>Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL).</description>
          <population>Per-protocol analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="71.24"/>
                    <measurement group_id="O2" value="-18.62" spread="62.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Thrombotic Biomarker Plasminogen Activator Inhibitor-1 (PAI-1)</title>
        <description>PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Thrombotic Biomarker Plasminogen Activator Inhibitor-1 (PAI-1)</title>
          <description>PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL).</description>
          <population>Per-protocol analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.17" spread="25.35"/>
                    <measurement group_id="O2" value="8.15" spread="30.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Inflammatory Biomarker Interleukin 6 (IL-6)</title>
        <description>IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Inflammatory Biomarker Interleukin 6 (IL-6)</title>
          <description>IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL).</description>
          <population>Per protocol analysis</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="1.44"/>
                    <measurement group_id="O2" value="-1.42" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Inflammatory Biomarker C-Reactive Protein (CRP)</title>
        <description>CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Inflammatory Biomarker C-Reactive Protein (CRP)</title>
          <description>CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL).</description>
          <population>Per-protocol analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.22"/>
                    <measurement group_id="O2" value="-0.15" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inflammatory Biomarker Tumor Necrosis Factor-alpha (TNF-α)</title>
        <description>TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL).</description>
        <time_frame>Baseline, 3 month</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Biomarker Tumor Necrosis Factor-alpha (TNF-α)</title>
          <description>TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL).</description>
          <population>Per-protocol analysis</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.21"/>
                    <measurement group_id="O2" value="0.18" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Inflammatory Biomarker Adiponectin</title>
        <description>Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Inflammatory Biomarker Adiponectin</title>
          <description>Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL).</description>
          <population>Per-protocol analysis</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" spread="5.22"/>
                    <measurement group_id="O2" value="0.46" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Body Mass Index</title>
        <description>Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Mass Index</title>
          <description>Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.</description>
          <population>Per-protocol population</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.62"/>
                    <measurement group_id="O2" value="-0.21" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Body Fat</title>
        <description>Body fat is reported as a percentage of body weight.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Fat</title>
          <description>Body fat is reported as a percentage of body weight.</description>
          <population>Per-protocol population</population>
          <units>percentage of body weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="3.08"/>
                    <measurement group_id="O2" value="-0.01" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Fat-Free Mass (FFM)</title>
        <description>FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg).</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Per-protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Sensitizer Therapy</title>
            <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fat-Free Mass (FFM)</title>
          <description>FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg).</description>
          <population>Per-protocol analysis</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="2.81"/>
                    <measurement group_id="O2" value="-0.34" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Insulin Sensitizer Therapy</title>
          <description>Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily. The number of subjects analyzed for baseline measures and outcome measures were the 12 subjects who completed the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets were used to match the active comparator drugs and dosing regimen. The number of subjects analyzed for baseline measures and outcome measures were the 13 subjects who completed the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>K. Sreekumaran Nair, MD, Ph.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-3605</phone>
      <email>nair@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

